局部复发前列腺癌挽救性近距离放疗:高剂量率与低剂量率疗效及毒性比较
本研究回顾性分析了2001至2016年间119例根治性放疗后活检证实局部复发的前列腺癌患者,分别接受低剂量率(LDR,n=44)或高剂量率(HDR,n=75)挽救性近距离放疗。中位随访52个月,5年前列腺特异性抗原(PSA)无复发生存率为71%,两组间无显著差异(p=0.063),毒性亦无显著差异。结论认为两种技术疗效与毒性相当。
要点
- 挽救性BT后5年PSA无复发生存率71%,HDR与LDR组无显著差异(p=0.063)。
- LDR组与HDR组5年病因特异性生存率分别为96.5%和93%。
- 挽救后PSA最低值和初治放疗至生化失败时间<30个月是进展预测因素。
核心结论
- HDR-BT与LDR-BT在局部复发前列腺癌挽救治疗中疗效和毒性相当。
研究设计与样本
- 多中心回顾性研究,纳入2001至2016年119例活检证实局部复发的前列腺癌患者,接受挽救性BT(LDR n=44,HDR n=75)。
主要发现
- 中位随访52个月,5年PSA无复发生存率为71%(95%CI 65.9%-75.9%),组间无显著差异(p=0.063)。
- LDR组和HDR组5年病因特异性生存率分别为96.5%和93%。
- 38例(32%)患者挽救性BT后出现生化进展(Phoenix定义),LDR组14例(32%),HDR组24例(32.5%)。
- 多因素分析显示,初治放疗至生化失败时间<30个月(p=0.014)和挽救后PSA最低值(p=0.000)与进展显著相关。
- 毒性无显著组间差异,≥3级毒性发生率为23.5%,包括尿道狭窄13例、尿失禁22例、血尿13例。
关键数值与推荐
- 5年PSA无复发生存率71%(95%CI 65.9%-75.9%)。
- LDR组和HDR组5年病因特异性生存率分别为96.5%和93%。
- 生化进展(Phoenix定义)总体32%,LDR组32%,HDR组32.5%。
- 初治放疗至生化失败时间<30个月与进展显著相关(p=0.014)。
- 挽救后PSA最低值与进展显著相关(p=0.000)。
临床怎么用
- 对于根治性放疗后局部复发的前列腺癌,HDR-BT和LDR-BT均可作为挽救治疗选择,疗效与毒性相当。
- 初治放疗至生化失败时间<30个月及挽救后PSA最低值较高提示预后较差,需加强随访。
局限性
- 回顾性研究设计,样本量有限,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brachytherapy (BT) is widely used for salvage therapy in patients with biochemical failure (BF) after radiotherapy for prostate cancer (PCa). Although low-dose-rate (LDR) and high-dose-rate (HDR) BT are both used for salvage therapy, it is not clear whether there are any differences between these two approaches in terms of efficacy or toxicity in this setting. Therefore, we review the institutional experience of the members of the Urological Tumour Working Group (URONCOR) of the Spanish Society of Radiation Oncology (SEOR) to compare these two techniques. METHODS AND MATERIALS: Between 2001 and 2016, 119 patients with biopsy-proven, locally-recurrent PCa underwent salvage BT (LDR, n = 44; HDR, n = 75) after primary radiotherapy. Relapse-free survival (RFS) and cause-specific survival (CSS) after salvage therapy were analyzed. Toxicity was assessed according to the RTOG scale. RESULTS: Median follow-up after salvage BT was 52 months. Overall, the 5-year prostate-specific antigen (PSA) RFS rate was 71% (95% CI, 65.9%-75.9%). No significant between-group differences in RFS were observed (p = 0.063). Five-year CSS for the LDR- and HDR-BT groups were 96.5% and 93%, respectively. Overall, 38 patients (32%) developed biochemical progression (Phoenix definition) after salvage BT: 14 patients (32%) in the LDR group and 24 (32.5%) in the HDR group. On the multivariate analysis, the following variables were significantly associated with progression, time to BF from primary radiotherapy <30 months (p = 0.014); and post-salvage nadir PSA (p = 0.000). There were no significant between-group differences in toxicity. Overall, there were 13 cases of urethral stricture, 22 cases of urinary incontinence, and 13 cases of haematuria. Toxicity ≥grade 3 was observed in 23.5% of patients. CONCLUSIONS: These findings show that both HDR-BT and LDR-BT yield comparable efficacy and toxicity outcomes in patients undergoing salvage treatment for locally-recurrent prostate cancer after primary radiotherapy. Predictors of worse outcomes after salvage BT were post-salvage nadir PSA and time to BF from initial radiotherapy.
引用
- Henríquez López I, González-San Segundo C, Vegas JO, et al. Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy. Radiother Oncol. 2019. PMID: 31570236. doi:10.1016/j.radonc.2019.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。